Objective:

To review recent advances in the therapeutic pipeline for Stargardt disease (STGD), emphasizing the urgent need for effective treatments through gene-targeted and gene-agnostic approaches.

Key Findings:

• ALK-001 significantly slowed atrophic lesion progression by 21.6% over 24 months in the TEASE-1 trial, indicating its potential as a disease-modifying therapy.
• Tinlarebant showed a trend toward slowing the expansion of atrophic lesions and stabilizing visual acuity in adolescents, suggesting its promise in early intervention.
• Emixustat did not meet its primary endpoint in the phase 3 SeaSTAR trial for reducing macular atrophy progression, raising questions about its efficacy.
• Metformin has shown potential in preclinical models for reducing lipofuscin buildup and photoreceptor loss, indicating a novel approach to STGD treatment.

Interpretation:

The findings suggest that novel therapies, particularly ALK-001 and tinlarebant, may offer promising disease-modifying effects in STGD, although emixustat's efficacy remains uncertain, highlighting the need for further research.

Limitations:

• The article does not provide long-term efficacy data for all therapies discussed, particularly for emixustat and metformin.
• Some trials are still ongoing, limiting the availability of conclusive results and necessitating cautious interpretation of preliminary findings.

Conclusion:

While no approved therapies currently exist for STGD, ongoing clinical trials and novel therapeutic strategies show potential for modifying disease progression and improving patient outcomes, underscoring the importance of continued research in this area.